Pipeline

Back to overview

AIC649 and IMI CARE approaches

Combatting pandemic viruses such as SARS-CoV-2

AIC649 in Pandemic Preparedness

We are currently experiencing an ongoing pandemic around the world caused by the beta
coronavirus SARS-CoV-2. As SARS-CoV-2 is a novel human coronavirus, there is no relevant herd
immunity in the population yet, and mutant viruses are appearing at concerning speed. With each
new virus spread, a certain time gap is unavoidable before new vaccines are available. AiCuris is
currently developing an inactivated parapoxvirus, AIC649. In pre-clinical experiments, AIC649
demonstrated anti-viral activity in prophylactic and/or treatment settings against several viruses
(e.g., HBV, HCV, HSV, Influenza, HIV/SIV, SARS-CoV-2). In addition to its primary indication HBV,
AIC649 is thus currently additionally being investigated as a preemptive treatment for SARS-CoV-2
infection.

A pilot study involving 60 subjects in Germany and South Africa has now started, with initial results expected in early 2022. Participation is open to people who have not been vaccinated against Corona and can provide a current positive test. In Berlin, interested parties can contact the emovis study center for advice on participating in the study: www.emovis.de/corona.

More importantly, a further broad prophylactic use of AIC649 for current and future viral pandemics of unknown origin will be evaluated.

  Partly funded by the German state of North-Rhine-Westfalia

IMI CARE

In addition, AiCuris is a partner in the IMI CARE project, Europe’s largest initiative to accelerate
therapy development for COVID-19 and future coronavirus threats.